Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Non-Tech : Enamelon (ENML) - Does anyone follow this? -- Ignore unavailable to you. Want to Upgrade?

To: DLS who wrote (393)	1/22/1998 12:42:00 AM
From: Greg B.	Respond to of 863

Everyone else is probably too busy day trading this stock. The conclusion is speculation, but consider the timing of the Dec 31st press release, the last day you could sell your shares for a loss in 1997; look at the timing of the Barron's article from a technical perspective, the timing of the secondary offering and the daily volume recorded around then. After the Dec 31st press release, the underwriters had plenty of time to issue reiterations based on the (expected) pilot clinical results. A guy on Yahoo chat tips everyone off to the Enamelon advertising campaign and roll-out activities; yet the underwriters remained silent. It wasn't until the news "leaked" day-before-yesterday morning, but it seems somebody delayed its release until they maximized the buying at low 12s. The spread became very tight. (By the way, after I posted that note, I double-checked my positions and an ENML market order wasn't executed for some reason, coincidentally just minutes before the news hit the street. That has never happened before, and raises additional suspicions, and there's nothing anyone can do about it. Financially, it's no big deal; it's just a matter of principle.) Perhaps the lesson here is stop talking about specific trading strategies, because that might cause the market makers to wag the dog. Harry: I'll also keep on the lookout for Lehman's report.